drugset / Trial / NCT03961256

Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

NCT03961256 ↗

Phase 2 Completed 9 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.

Timeline

Start
2019-05-09
Primary completion
2021-10-18
Completion
2021-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide SR Unknown 2 mg Subcutaneous

Indications